Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors
NCT04552847Phase 3Completed
- Sponsor
- UZ Leuven
- Start
- Oct 2020
- Primary completion
- Feb 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of 18F-AlF-NOTA-octreotide in neuroendocrine tumors (NETs), sponsored by UZ Leuven. Started Oct 2020; status: completed.
02
Drugs
18F-AlF-NOTA-octreotide
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT04552847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04552847.